Ritholtz Wealth Management Buys 5,215 Shares of Johnson & Johnson $JNJ

Ritholtz Wealth Management raised its stake in Johnson & Johnson (NYSE:JNJ) by 5.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 106,447 shares of the company’s stock after acquiring an additional 5,215 shares during the period. Ritholtz Wealth Management’s holdings in Johnson & Johnson were worth $28,181,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. NBH Bank grew its stake in Johnson & Johnson by 3.3% during the third quarter. NBH Bank now owns 11,716 shares of the company’s stock worth $3,102,000 after buying an additional 370 shares in the last quarter. Joel Isaacson & Co. LLC raised its position in shares of Johnson & Johnson by 6.2% in the 3rd quarter. Joel Isaacson & Co. LLC now owns 84,340 shares of the company’s stock valued at $22,328,000 after buying an additional 4,944 shares in the last quarter. International Private Wealth Advisors LLC acquired a new position in shares of Johnson & Johnson in the 3rd quarter valued at approximately $258,000. DSG Capital Advisors LLC lifted its holdings in shares of Johnson & Johnson by 1.2% during the 3rd quarter. DSG Capital Advisors LLC now owns 20,000 shares of the company’s stock worth $5,295,000 after acquiring an additional 230 shares during the period. Finally, Silver Grove Financial Group Inc. lifted its holdings in shares of Johnson & Johnson by 12.9% during the 3rd quarter. Silver Grove Financial Group Inc. now owns 1,940 shares of the company’s stock worth $514,000 after acquiring an additional 222 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on JNJ shares. TD Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 20th. Royal Bank Of Canada lowered their price objective on shares of Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating for the company in a research report on Wednesday, October 14th. Weiss Ratings cut Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a research note on Friday, October 23rd. Johnson Rice cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. Finally, JPMorgan Chase & Co. raised their target price on Johnson & Johnson from $270.00 to $285.00 and gave the company a “neutral” rating in a report on Tuesday, September 29th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $275.92.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This represents a 7.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. This represents a 56.90% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $280.52 on Thursday. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The stock has a market cap of $675.29 billion, a PE ratio of 42.50, a P/E/G ratio of 2.78 and a beta of 0.22. Johnson & Johnson has a 12-month low of $193.07 and a 12-month high of $283.25. The business’s 50-day moving average price is $266.67 and its two-hundred day moving average price is $249.23.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm had revenue of $25.40 billion during the quarter, compared to analysts’ expectations of $25.38 billion. During the same quarter in the prior year, the business earned $2.80 earnings per share. The business’s revenue for the quarter was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, analysts expect that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is currently 81.21%.

Johnson & Johnson News Summary

Investors following JNJ have been watching these news items:

• Positive Sentiment: J&J reported that a second pivotal Phase 3 trial of CAPLYTA met its primary and key secondary endpoints for bipolar I mania, with symptom improvement seen as early as Day 3. The two positive trials support a planned U.S. FDA submission, adding a potential growth opportunity. Reuters article
• Neutral Sentiment: J&J shares have risen substantially in recent years, prompting questions about whether expected cash flows justify the valuation; this could limit further gains if expectations are already reflected in the stock. Separately, a State Street health-care ETF sold J&J shares while reducing all of its holdings, which does not appear to be a company-specific signal. Valuation article
• Negative Sentiment: A Massachusetts jury awarded $3.3 million, including interest, to a family in a mesothelioma case tied to J&J talc-based baby powder. The award adds to the company’s ongoing talc litigation exposure. Verdict announcement

Johnson & Johnson Company Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.